Compare MCHB & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCHB | RARE |
|---|---|---|
| Founded | 1905 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | N/A | 2013 |
| Metric | MCHB | RARE |
|---|---|---|
| Price | $15.64 | $34.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 20 |
| Target Price | $15.75 | ★ $59.10 |
| AVG Volume (30 Days) | 483.2K | ★ 3.0M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.53% | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $673,000,000.00 |
| Revenue This Year | $43.32 | $13.12 |
| Revenue Next Year | N/A | $37.80 |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $12.82 | $18.29 |
| 52 Week High | $16.53 | $39.89 |
| Indicator | MCHB | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 72.15 |
| Support Level | $13.90 | $31.82 |
| Resistance Level | $15.71 | $35.95 |
| Average True Range (ATR) | 0.39 | 1.72 |
| MACD | 0.03 | 0.63 |
| Stochastic Oscillator | 57.70 | 81.88 |
Mechanics Bancorp is an independent, full-service community bank. It provides personal banking, business banking, trust and estate, brokerage and wealth management services. its retail banking products include personal checking, savings, and loan products (including credit card, home equity, home mortgage, and secured/unsecured loans), online banking, and wealth management services (including trust and estate, investment management, and financial planning services). its banking products and services for businesses include business checking and savings accounts, business debit cards, online banking, cash management services, wealth management services, business credit cards, commercial real estate loans, equipment leasing, and loans guaranteed by the Small Business Administration.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.